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Abstract
Objective—Chemokine receptors are G-protein coupled receptors (GPCRs) phosphorylated by G-
protein receptor kinases (GRKs) after ligand-mediated activation. We hypothesized that GRK
subtypes differentially regulate granulocyte chemotaxis and clinical disease expression in the K/BxN
model.
Methods—Clinical, histologic, and cytokine responses in GRK6−/−, GRK5−/−,GRK2+/−, and
wildtype mice were evaluated using K/BxN serum transfer. Granulocyte chemotaxis was analyzed
by transendothelial migration assays.
Results—Both GRK6−/− and GRK2+/− mice had increased arthritis disease severity (p<0.001);
whereas GRK5−/− was not different from controls. Acute weight loss was enhanced in GRK6−/−
and GRK2+/− mice (p<0.001, days 3–10). However, GRK6−/− mice uniquely had more weight loss
(>10%), elevated serum IL-6, and enhanced migration toward LTB4 and C5a in vitro.
Conclusions—GRK6 and - 2, but not GRK5,are involved in the pathogenesis of acute arthritis in
the K/BxN model. In particular, GRK6 may dampen inflammatory responses by regulating
granulocyte trafficking toward chemoattractants.
G protein coupled receptors (GPCRs) are seven transmembrane spanning receptors that
represent the largest superfamily of membrane-bound receptors in nature. With respect to
immune function, GPCR-ligand interactions play critical roles in organ-specific leukocyte
trafficking and activation, inflammatory-mediated chemotaxis, effector cell function, and cell
survival [1;2]. Consequently, the regulation of GPCRs and their downstream signaling
molecules are attractive therapeutic targets for patients with autoimmune disease.
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GPCR-mediated signaling maintains a coordinated balance between receptor activation,
desensitization, and subsequent resensitization. G-protein receptor kinases (GRKs) are a family
of molecules that play a critical role in the desensitization process of activated GPCRs [3;4].
Specifically, GRKs phosphorylate only ligand-bound and activated GPCRs, leading to rapid
uncoupling of the receptor from heterotrimeric G proteins and subsequent homologous
desensitization [4;5].
There are 7 different subtypes of GRKs [6] that have varying tissue distribution, suggesting
some non-overlapping regulation of cellular functions. GRK1 and -7 are exclusively expressed
in the retinal rods and cones respectively, and GRK4 has a high level of expression in the testes
and a low level in kidney and cerebellum [7]. GRK subtypes -2, -3, -5, and -6 are expressed
ubiquitously but have particularly high expression in leukocytes [8;9;10]. Moreover, GRK
subtypes appear to be differently regulated in inflammatory disease states. Specifically, GRK6
and -2 protein levels are downregulated within peripheral blood mononuclear cells of
rheumatoid arthritis patients [11]. In the rat model of adjuvant arthritis, GRK6 and -2 are
decreased >50% in lymphoid organs at the peak of the inflammatory process, which
subsequently normalized during the remission phase of the disease [12]. These observations
suggest that GRKs play an important regulatory role in immune function and could have a
more critical role in autoimmune disease states.
In gene deletion studies, deficiencies in GRK6 or -2 have been shown to specifically affect the
migration of leukocyte subsets both in vitro and in vivo [13;14]. In specific, GRK6-deficient
(GRK6−/−) mice have increased granulocyte infiltration in the AA-induced ear inflammation
model after topical arachadonic acid is applied [14]. GRK6−/− mice also have enhanced
granulocyte-mediated inflammation of the gut in a dextran sodium sulfate (DSS)-induced
colitis model [15]. In contrast, in vitro work has shown reduced lymphocyte chemotaxis in
GRK6−/− T cells to CXCL12 [13]. GRK2 heterozygote mice (GRK2+/−) have been evaluated
in the animal model of multiple sclerosis, (experimental allergic encephalomyelitis, EAE) since
homozygotes are embryonic lethal due to cardiac dysgenesis [16]. T cells and macrophages
were increased in the central nervous system of GRK2+/− mice in the early stages of disease,
followed by a reduction in the inflammatory cell infiltrate at later time points [17].
Given the aforementioned data supporting GRK involvement in inflammatory disease
expression in vivo and in leukocyte trafficking in vitro, we hypothesized that GRK6 and -2
may be involved in the pathogenesis of inflammatory arthritis via effects on chemotaxis. To
test this, we performed studies using the K/BxN serum transfer mouse model of acute
inflammatory arthritis [18] where the serum from K/BxN mice can transfer disease to naive
recipients [19], resulting in bony erosions similar to human rheumatoid arthritis [20]. The K/
BxN serum transfer model is notably independent of both B and T cells, whereas granulocytes
are critical for disease [21]. Consequently, this model enables us to examine the regulatory
effects of GRK2, -5, and -6 gene deletions that are independent of the lymphocytic induction
phase of disease and more reflective of the effector immune response.
Materials and Methods
Animals
Animals used in these experiments were backcrossed ≥9 generations onto the C57/Bl6 strain
with littermate controls. All animals were bred, housed, and cared for in DLAM facilities under
the approved IACUC protocol number 03–265.0 in pathogen free specific conditions.
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Induction and evaluation of K/BxN arthritis
Male 6 week old mice heterozygous for GRK2 or deficient in GRK5 or -6 and wild-type
littermates were injected on days 0 and 2 with a dose of 5 µl K/BxN serum per gram of mouse
weight intraperitoneally. Mice were measured daily for endpoints of paw swelling, clinical
disease index, and weight. Paw swelling was represented as a change in the mean thickness of
the mouse’s fore- and hindlimbs (mm) from its baseline average and was obtained by a blinded
measurer. Clinical index was assessed as the consensus of 2 blinded observers with the
following scoring system: 0=normal paw; 1=mild but definite swelling of either the ankle or
digits; 2=moderate redness and swelling of an ankle ± any number of digits; 3=maximal redness
and swelling of the entire paw and digits. The maximum score per paw obtainable being 3 with
a total of 12 per mouse. Results for paw swelling and clinical index are reported as an average
in the total score ± SEM for the group. At experiment termination, hindlimbs were fixed for
24h in 4% paraformaldehyde, decalcified using formic acid for 24–48h, and embedded in
paraffin for histopathology.
Histopathology
Histopathology sections of the hindlimbs were stained with hematoxylin and eosin and were
scored by a blinded observer for the severity of inflammatory cell infiltrate and the presence
of erosions using the following scoring system: 0=normal paw; 1=mild inflammatory cell
infiltrate with minimal synovial thickening and no architectural distortion; 2=moderate
inflammatory cell infiltrate with enhanced synovial proliferation without erosions; 3=severe
inflammatory cell infiltrate with erosions.
Transendothelial migration assays
Transendothelial migration (TEM) assays were performed as previously described [13].
Briefly, 104 Ea.hy 926 endothelial cells were plated onto 24-well (5 µm) Transwells and
incubated for 7 days. Monolayer integrity was determined by [14C] mannitol diffusion. For
migration studies, the medium in the bottom chamber was replaced with medium or
chemoattractant (10 nM LTB4,100 nM C5a; Sigma-Aldrich, St. Louis, MO, or hIL-8 100ng/
ml; R&D Systems, Minneapolis, MN) and primary bone marrow cells isolated from individual
mice of the respective GRK genotypes were added to the top chamber. Following 4 h of
incubation at 37°C, cells in the lower chamber were harvested and stained with anti-mouse
Gr-1 conjugated to PE (BD Biosciences, San Diego, CA). The number of migrated granulocytes
was determined by flow cytometry.
Serum cytokine analysis
Mouse blood was collected by tail vein nick on days 0, 4, and 8 after immunization with K/
BxN mouse serum on days 0 and 2. Cytokine measurements were performed using a Millipore
Beadlyte Multiplex assay (Millipore Corporation, Billerica, MA), and analyzed on a Luminex
100 Total System v.1.7 (Luminex Corporation, Austin, Texas) according to the manufacturer’s
protocol. Data were analyzed using Starstation v.2.0 (Applied Cytometry Systems,
Sacramento, CA).
Data analysis
For clinical index, paw swelling, and % weight loss curves, a statistical curve-fit was used to
determine whether significant differences existed in the course of the disease over time between
the GRK deficient mice versus wildtype controls. A backward selection (α=.05) procedure was
used to select a linear mixed model with the best fit for the individual curves. Variables
considered in the statistical analysis included group, time, and experiment effect. The overall
group effect was assessed using a likelihood ratio test (LRT) (α=.05). The best fit curves were
plotted using predicted values calculated using the fixed effects from the models, averaging
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across experiment, which was controlled for if it was a significant (α=.05) predictor in the
model. Statistical analysis was performed using SAS, v. 9.1. For transendothelial migration
assay results, an unpaired two-tailed Ttest was used to compare the means between groups.
IL-1 and IL-6 systemic cytokine production was analyzed using an unpaired single-tailed Ttest
to compare the means between groups.
Results
GRK6−/− and GRK2+/− mice have more severe arthritis early in the K/BxN model compared
to controls
To investigate whether or not the reduction in GRK expression previously described in
rheumatoid arthritis patients [11] directly contributes to the pathophysiology of inflammatory
arthritis in our animal model, we examined GRK6−/−, GRK2+/−, GRK5−/−, and wildtype
mice in the K/BxN serum transfer model. We found that animals with a targeted genetic
deletion of GRK6 had the most pronounced enhanced arthritis early in their disease compared
to their wildtype littermate controls by two independent measures of paw swelling (p<0.0001)
and clinical disease severity index (p<0.0003) (Figure 1A, Figure 2A). Although GRK2+/−
mice also showed enhanced disease compared to controls by paw swelling (p<0.0001) and
clinical disease index (p=0.0003) (Figure 1B, Figure 2B), it was not as severe as GRK6−/−
animals. In contrast, GRK5−/− mice had similar disease indices when compared to wildtypes
(Figure 1C, Figure 2C), suggesting that the observed effects were specific and differing
between the GRK subtype.
To investigate whether or not the earlier disease enhancement observed in the GRK6−/− and
GRK2+/− mice translated into chronic disease differences, we examined histopathology of the
hindlimbs at experiment termination (day 22 or 23) by hematoxylin and eosin staining. There
were no substantial differences between the different GRK genotypes and the wildtype controls
with respect to the severity of inflammation or bony erosions at the later stage of disease (Figure
3).
Granulocytes from GRK6−/− mice have enhanced chemotaxis to LTB4 and C5a, but not to
IL-8, in vitro
LTB4 and C5a are potent chemoattractants for granulocytes and signal through their respective
GPCRs (BLT and C5aR). Disease expression in the K/BxN serum transfer model is critically
dependent on granulocytes [21] as well as LTB4 [22] and C5a [23]. Therefore, we hypothesized
that the enhanced disease seen in the GRK6 and -2 deficient mice may be mediated through
interactions with the BLT and C5a receptors on granulocytes. In agreement with a previous
report [14], we found that GRK6−/− granulocytes have enhanced chemotaxis to LTB4 in
vitro (p=0.0042) that is approximately 30% more compared to wildtype cells (Figure 4). We
also show that GRK6−/− granulocytes have 30% more chemotaxis toward C5a (p=0.0074)
(Figure 4). Interleukin-8 (IL-8 or CXCL8) is also a potent chemoattractant of granulocytes and
signals through the GPCR, CXCR1. However, migration to IL-8 was not different in any of
the GRK-deficient subtypes compared to wildtype controls (Figure 4).
While statistical significance was not reached (p=0.4074), GRK2+/− granulocytes had a trend
towards increased migration to LTB4 with approximately 15% enhanced migration compared
to wildtype cells. The migration of GRK2+/− granulocytes toward C5a (p=0.8753) was similar
to controls (Figure 4). These data suggest that the absence of GRK6, leading to increased
granulocyte migration, may enhance inflammation through a failure to desensitize signaling
of the LTB4 and C5a GPCRs (BLT1&2 and C5aR respectively), and partial GRK2 deficiency
may also play a role in BLT1&2 receptor signaling.
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GRK6−/− mice have enhanced systemic effects in the K/BxN model
In the K/BxN model, wildtype mice typically experience a reversible weight loss
approximating <5% of total body weight that begins during the acute inflammatory phase and
resolves with improved clinical arthritis scores (Figure 5 and unpublished observations). While
GRK5−/− mice had a similar level of weight loss compared to wildtypes, GRK6−/− mice had
a profound weight loss of >10% of their total body weight compared to that of controls
(p<0.0001) (Figure 5A). We hypothesized that this finding may result from increased
inflammation leading to enhanced systemic production of proinflammatory cytokines. Indeed,
GRK6−/− mice have increased IL-6 detectable in the serum (Figure 6A), which correlates
temporally with the nadir weight loss occurring between days 3–10. Systemic production of
IL-1β was detected in the serum but was not significantly different between GRK6-deficient
animals and controls (Figure 6B). Although GRK2+/− animals had an average 5% more weight
loss than wildtypes that was significant (p<0.0001) (Figure 5B), it was less pronounced than
GRK6−/− and the systemic cytokine profile did not differ significantly from that of wildtype
controls (data not shown). We attempted to measure TNF-α in the serum in addition to the
IL-1β and IL-6 of the GRK-deficient and wildtype mice, but it was rarely measured above the
limit of detection in the majority of samples for an analysis to be reliable (data not shown).
Discussion
GPCR-mediated leukocyte trafficking is critical in inflammatory disease states, and the GRK
regulatory system has been implicated in animal models of autoimmune disease. Recently,
GRK6-deficient animals have been shown to have increased neutrophil migration to the gut
and impaired regulatory T cell responses in a DSS-induced colitis model of inflammatory
bowel disease [15]. In the EAE model of multiple sclerosis, GRK2 heterozygote animals
exhibit earlier inflammation that correlates with T cell and macrophage infiltration into the
CNS, but then subsequently have less disease and inflammatory cell infiltrate than wildtype
controls at later time points [17]. Given that GRK6 and -2 levels are reduced in disease flares
of adjuvant induced arthritis [12] and in the PBMC of rheumatoid arthritis patients [11], we
investigated how and which GRK subtypes play a role in leukocyte migration to the joint in
an acute model of inflammatory arthritis, the K/BxN serum transfer model. This model system
closely mirrors the acute flares of rheumatoid arthritis and allowed us to evaluate mononuclear
cell contribution toward disease independent of the lymphocytic response.
The in vitro studies further support a role for GRK6 and -2 in granulocyte-mediated chemotaxis
to LTB4 and C5a (Fig 3). LTB4 is a potent neutrophil chemoattractant [24] and critical for
disease in the K/BxN model [22]. One of its high affinity receptors (BLT1) is a GPCR that has
been shown to have GRK6 and -2 mediated receptor internalization [25] and desensitization
[26] respectively. Previous work by Kavelaars et al. has demonstrated enhanced chemotaxis
in GRK6 deficient granulocytes in vitro to LTB4 [14], and our data here support this finding.
We also show that GRK6 deficient granulocytes have enhanced chemotaxis to C5a compared
to controls. The C5a anaphylatoxin receptor (C5aR) is a GPCR important in the chemotaxis
and activation of myeloid cells [27] and necessary for K/BxN disease expression [23]. Over
expression of wildtype or catalytically inactive forms of GRK6 and -2 in COS-7 cells does not
change agonist-mediated phosphorylation of C5aR [28]. However, Milcent et. al. noted that
transfection of COS-7 cells with wildtype GRK6 consistently increased expression of C5aR
by two fold and that GRK6 appeared to be autophosphorylated [28], suggesting a biologic
relevance not apparent in this in vitro model system. Our data suggests that GRK6 may have
receptor-kinase interactions mediated through the BLT and C5aR receptors on granulocytes
that are physiologically relevant as it pertains to inflammatory disease.
Interleukin-8 (IL-8 or CXCL8) is also a known chemoattractant of granulocytes and is thought
to have pathophysiologic significance in rheumatoid arthritis through its chemoattractant
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[29] and angiogenic [30] properties. However, we did not observe differences in granulocyte
migration to IL-8 in the animals with gene defects in GRK2, -5, or -6 compared to controls
(Figure 4). The role of IL-8 in the K/BxN model in specific is largely unknown, whereas LTB4
and C5a in this model have been found to be of critical importance to disease pathogenesis
[22;23].
Our data also suggest that the enhanced inflammatory disease seen in GRK2 heterozygote mice
may be mediated through one or both of the BLT GPCRs. GRK2+/− granulocytes have slightly
increased chemotaxis to LTB4 in vitro, albeit our results did not achieve statistical significance.
This could be partially explained by the heterozygous expression of GRK2 that may have
reduced this phenotype. Further support that GRK2 plays an important role in BLT1 signaling
has been suggested in transfection model systems [25]. LTB4-induced internalization of BLT1
can be blocked by dominant negative GRK2 co-expression, and GRK2 co-localizes with the
BLT1 receptor through the C terminus [25].
We also show that in addition to increased organ-specific inflammation, GRK6-deficient
animals have enhanced systemic effects in the K/BxN model. Weight loss is observed in
inflammatory disease states such as rheumatoid arthritis and has been linked to elevated
cytokine production, particularly TNF-α [31]. We were unable to reliably detect TNF-α in the
serum of our arthritic animals to investigate its role in the cachexia, but we do show that GRK6
−/− animals have elevated systemic levels of IL-6 that coincide with the observed weight loss.
IL-6 can be elevated in rheumatoid arthritis patients and may correlate with disease activity
[32]. In addition, IL-6 has been associated with profound cachectic states such as malignancy
[33;34]. Importantly, IL-6 is not elevated chronically in the K/BxN model in either wildtypes
or GRK6-deficient animals (Figure 6A and unpublished observations), and the presence of
malignancy has not been observed in the K/BxN model in either controls or GRK-deficient
mice.
Unlike the DSS-colitis model studied by Kavelaars et al., we did not observe significant
differences in systemic production of IL-1β between groups [15]. This could be explained by
the different types of inflammatory responses being observed (i.e. DSS, chronic v. K/BxN,
acute) or by different pathophysiologic mechanisms regulating the two disease models.
Although we did observe increased weight loss in the GRK2+/− mice, we did not detect any
significant differences in systemic cytokine production, possibly because their overall weight
loss and disease was less severe.
In conclusion, the GRK system is an important regulatory pathway in the K/BxN serum transfer
model of arthritis, particularly as it pertains to the early infiltration of granulocyte-mediated
acute inflammatory responses. Granulocytes, which are critical to disease expression in the K/
BxN model, have increased chemotaxis to LTB4 and C5a, but not IL-8, and GRK6−/− mice
have more arthritis, weight loss, and IL-6 production. These data highlight the unique and
subtype-specific effects of the GRKs on leukocyte trafficking and inflammatory disease and
underscore the important regulatory role that GRK molecules may play in the acute versus
chronic phases of autoimmunity. Although specific gene polymorphisms in the GRKs have
not been described in the human rheumatoid arthritis population, an increased understanding
of these regulators as they pertain to acute versus chronic inflammatory cell trafficking may
lead to targeted therapies or diagnostics for patients with rheumatoid arthritis or other
autoinflammatory diseases.
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Figure 1. Paw swelling is increased in animals deficient in GRK 6 and -2, but not -5,compared to
wildtype controls
Shown is the mean difference in mm swelling from baseline thickness of the ankles of wildtype
and GRK-deficient animals (± SEM) over time in days. The data are combined from 3 (GRK6
−/−) and 2 (GRK2+/− and GRK5−/−) separate experiments. A. GRK6−/− mice have the most
disease severity that is more pronounced earlier in the disease course (LRT=56, 3 df, p<0.0001;
GRK6−/− n=14, WT n=13). B. GRK2 +/− mice also show enhanced disease (LRT=32.4, 3 df,
p<0.0001; GRK2+/− n=12, WT n=13). C. GRK5−/− mice do not differ from wildtype controls
(LRT=1.3, df=2, p=0.522; GRK5−/− n=11, WT n=13).
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Figure 2. Clinical index of disease activity is increased in animals deficient in GRK6 and -2, but
not -5, compared to wildtype controls
Shown is the mean clinical index ± SEM over time in days as determined by the summation
of each paw scored on a scale of 0–3 and averaged for the group. The data are combined from
3 (GRK6−/−) and 2 (GRK2+/− and GRK5−/−) separate experiments. A. GRK6−/− mice have
the most disease severity that is more pronounced earlier in the disease course (LRT=19, 3 df,
p<0.0003; GRK6−/− n=14, WT n=13). B. GRK2 +/− mice also show enhanced disease
(LRT=18.9, 3 df, p=0.0003; GRK2+/− n=12, WT n=13). C. GRK5−/− mice do not differ from
wildtype controls (LRT=6.1,df=3, p=0.1068; GRK5−/− n=11, WT n=13).
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Figure 3. Late stage inflammatory disease and erosions do not differ between the GRK genotypes
and wildtype controls in the K/BxN model
Shown is representative H&E histology at experiment termination (Day 22 or 23) of A.
wildtype, B. GRK6−/−, C. GRK2 +/−, and D. GRK5−/− mice. The severity of inflammatory
infiltrate and erosions did not differ between groups;↑ localize the erosions on hematoxylin
and eosin stained sections.
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Figure 4. GRK6 deficient mice have increased granulocyte migration to LTB4 and C5a, but not
IL-8, in vitro compared to wildtype controls
The migration of granulocytes in response to 10 nM LTB4,100 nM C5a, or 100 ng/ml IL-8
were determined by anti-Gr-1 staining and flow cytometry of migrated primary bone marrow
cells of the different murine GRK genotypes compared to wildtype. Data are represented as %
migration of the total input (i.e. total number of anti-Gr-1 positive cells harvested from the
lower chamber divided by the total number of anti-Gr-1 positive cells in the upper chamber)
± SEM, n=6. Only GRK6−/− granulocytes show statistically increased migration to LTB4 (§,
p≤0.01) and C5a (*, p≤0.01). There was no difference between migration of the different GRK
genotypes compared to wildtypes in response to IL-8.
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Figure 5. GRK6-deficient animals demonstrate maximum acute weight loss in the K/BxN model
that reverses with disease improvement
Data is represented as a mean of the change in % weight from an individual animal’s baseline
= 1.0 of wildtype and GRK-deficient animals (± SEM) over time in days. The data are combined
from 3 (GRK6−/−) and 2 (GRK2+/− and GRK5−/−) separate experiments. A. There is a
significant group effect indicating more weight loss in the GRK6−/− mice (LRT=102; df=3;
p-value<0.0001; GRK6−/− n=14, WT n=13). B. There is also a significant group effect in the
GRK2+/− mice (LRT=35.2; df=4; p-value<0.0001; GRK2+/− n=12, and WT n=13). C. There
is no significant difference between GRK5−/− animals and controls (LRT=2.7; df=2; p value=
0.2592; GRK5−/− n=11, and WT n=13).
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Figure 6. GRK6-deficient animals produce higher systemic levels of IL-6 compared to wildtype
controls in the K/BxN model of inflammatory arthritis
Data represent the mean serum cytokine production + SEM in pg/ml of A. IL-6, and B.
IL-1β on Days 0, 4, and 8 after i.p. injection with K/BxN serum. Results presented are from 2
separate experiments; GRK6−/− n=8, WT n=9. Animals were bled by tail vein nick, and serum
cytokine analysis was performed using an Upstate BeadLyte assay and interpreted on a
Luminex 100 instrument. GRK6−/− had statistically increased levels of systemic IL-6 on Day
4 (* p=0.05) compared to wildtype animals. Limit of detection of the assay was 18.7 pg/ml for
IL-6 and 4.8 pg/ml for IL-1β.
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